News | May 08, 2026
Roche moves to acquire PathAI for up to $1.05 billion in major AI pathology push
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
The private funding rose 38% amid growing international collaborations and CDMO demand
The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Subscribe To Our Newsletter & Stay Updated
